JPRN-UMIN000008769
Completed
Phase 2
Efficacy and Safety of Everolimus in Patients with Unresectable or Metastatic Renal Cell Carcinoma - Efficacy and Safety of Everolimus in Patients with Unresectable or Metastatic Renal Cell Carcinoma
Tokyo Afinitor Clinical Trial Group - RCC(TACT-R)0 sites120 target enrollmentOctober 1, 2012
Conditionsrenal cell carcinoma
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- renal cell carcinoma
- Sponsor
- Tokyo Afinitor Clinical Trial Group - RCC(TACT-R)
- Enrollment
- 120
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients with history of hypersensitivity against everolimus or sirolimus derivative 2\) Pregnant, pregnancy suspect, nursing women, patients who plan to have a baby 3\) Patients judged ineligible to participate in the study by the investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Efficacy and Safety of Everolimus in Patients with Non-Clear Cell Renal Cell Carcinomaon-clear cell renal cell carcinomaJPRN-UMIN000006248Yamaguchi University Graduate School of Medicine , Department of Urology10
Recruiting
Not Applicable
Clinical effects of everolimus in the subjects with autism spectrum disprders (ASD) in relation to tuberous sclerosis.there are a few individuals with TSC with SEGA who exhibite ASD symptoms.JPRN-jRCT1090220258Kunio Yui20
Completed
Phase 4
Maintenance therapy with Everolimus in patients with tuberous sclerosis successfully treated for subependymal giant cell astrocytomaQ85.1D33.0Tuberous sclerosisBrain, supratentorialDRKS00005584Medical University of Lodz12
Recruiting
Phase 2
Efficacy of 0.05%topical everolimus in the treatment of adenoma sebaceum in tuberous sclerosisadenoma sebaceumTCTR20180820002Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital15
Active, not recruiting
Phase 1
Introduction of everolimus is associated with a reduction in the dosage of calcineurine-inhibitors in patients with a pulmonary graft who suffer from a notable chronic renal insuffisance.Patient who received a pulmonary transplant and who show notable renale insuffisance (DFG < 50ml/min/1.73m²) which has been progressive over the last two years or chronical renal insuffisance which progresses fast (a los of >50% DGF in 3 months) and isotopical glomerural filtration < 45 ml/min.EUCTR2006-001945-32-BEB Erasme15